Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults - Wikidata - awgldk - TriplyDB

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

http://www.wikidata.org/entity/Q30439565

about

Circulating glioma biomarkers Blood-based biomarkers for malignant gliomas Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.Kaposiform hemangioendothelioma in multiple spinal levels without skin changes COX-2 overexpression increases malignant potential of human glioma cells through Id1.Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.Thalidomide-a notorious sedative to a wonder anticancer drug.Experimental approaches for the treatment of malignant gliomas.A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.ABCG1 maintains high-grade glioma survival in vitro and in vivo.Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Targeted therapy in the treatment of malignant gliomas Bevacizumab for the treatment of glioblastoma.Targeted therapy in gliomas.Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.Emerging circulating biomarkers in glioblastoma: promises and challenges.Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.New Directions in Anti-Angiogenic Therapy for Glioblastoma.Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress.Cancer stem cells: The potential role of autophagy, proteolysis, and cathepsins in glioblastoma stem cells.Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: relevant similarities to and important differences from celecoxib.The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-κB pathway.Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study.Knockdown of vascular endothelial cell growth factor expression sensitizes U251 glioma cells to liposomal paclitaxel and radiation treatment in vitro Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.Cox-2-derived PGE2 induces Id1-dependent radiation resistance and self-renewal in experimental glioblastoma.A structure- and chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase.Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.Drug Repurposing of Metabolic Agents in Malignant Glioma

P2860

Q26830329-E0299138-A85B-42AD-806D-CDE9CB40C43C Q30625411-92E1C933-6001-4059-8832-174D8F75DF93 Q31016728-5847064F-5E82-44B1-9513-3C263A624375 Q33384174-6D12B344-C50F-422D-9E5E-7E4FF3B00C30 Q33576867-A218F4DD-B154-4FDD-84AD-2B8CF932A5BA Q33819663-116B5A9D-9617-463D-9279-00BAECF1A281 Q33956871-33B4E939-A622-4432-9AF8-4AA16905BDBC Q34127138-D3BCCD98-71DE-4EE6-84AD-423322E2E211 Q34453644-8DE217A7-A599-46B4-9A60-DEF7E32F07B3 Q35895174-8A21953D-973C-4C25-B65C-C7D1D416EE98 Q35922107-A9FC0A33-C376-414B-9F75-43336F859D58 Q36833480-253FD4FD-A604-43EA-9E65-84AECE387DE2 Q37269034-1DA85D89-2B4A-4F23-AAA3-00A83F63BA4D Q37528441-B647FFFE-AE6B-49A9-B942-24D3E8DA3AFA Q37580396-92DE6DAE-D265-4892-A2CA-CA68FFC0F085 Q37736273-F994EFF4-631B-4476-A281-7A0F7DDC9DC8 Q37771247-4A7EF4CC-9C63-431D-B392-B701507D56B9 Q38129428-83367AD9-0A6E-40DB-B749-A9BFBDE5BAD7 Q38186656-9E083284-DCE1-4F5C-8F35-C4E4739F386C Q38587724-E5F895DA-C809-4E07-8652-87D4245EB3FB Q38591062-4CF23B44-C311-4AC0-8EEE-A9B77B816571 Q38624686-3062254E-5BD9-42C6-9140-F1B4CE657CA2 Q38720644-E2F0E1E5-28DB-4982-BBC4-B9E4C76D10A5 Q39022941-4D01B9F5-7014-4740-956C-79B961E80E17 Q39154529-3672A80D-62B3-40B1-9AEC-9399AC7341F6 Q39202839-74D54F09-3C8C-47EE-B80C-121E6CE09781 Q39218093-05C8D95D-1C0F-40CE-A660-B7334C8445D2 Q39489252-9BEE99C0-22B8-40B8-B6D3-3C7B05E1BC2B Q39513373-CF0211F3-3E79-4FF0-87DC-C81B88BB6415 Q39554437-00EE51BD-D230-4CCF-8411-3F92830B0B81 Q39696393-627A10E9-A292-4107-86D6-1C177392D028 Q41654291-5D3F7E66-D29B-43E0-94D7-515C403AD309 Q42315007-B53B3D58-A5B2-4CBC-AF25-6278C1371A6D Q49092861-CEBC56C4-EAF7-4903-9945-D11C7BA156F1 Q58738611-0B9C0B0B-9661-4429-8847-5FBA30C49E03

P2860

Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults

http://www.wikidata.org/entity/Q30439565

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@ast

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@en

type

label

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@ast

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@en

prefLabel

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@ast

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@en

P1433

Q30439565-3DCEBFC1-183B-4FA8-B19F-3509A4EEBDC2

P1476

Q30439565-F0BCD4B6-4CFD-4369-A440-C47E7DBEF040

P2093

Q30439565-0113CC65-D72D-43A4-BFF7-2B3296EEE44B

Q30439565-2A752A62-B100-4700-95B5-3E2A78719148

Q30439565-2F5B7EE5-4709-4A59-98ED-3EDD02CCE3B2

Q30439565-461AB96F-D3D9-4E89-A169-1CA2E9925D25

Q30439565-54006118-A054-42D1-A55E-098FFDA60F1A

Q30439565-5BA8AAF5-A082-495F-807F-7B7EE9043709

Q30439565-5D913E98-25DD-437F-81AF-BB372DE9025F

Q30439565-60C54899-5720-420E-BFE7-3098CAD187D6

Q30439565-6708600F-2832-498E-9B24-B49FDBCCA70C

Q30439565-6A4A712F-4C10-448C-A7B4-CEC2DC8B2C2F

P2860

Q30439565-11ED4A20-1C08-4E61-994C-29007DDC4F92

Q30439565-16C37655-896B-4A73-9772-75DBA95FBC5B

Q30439565-1753EAA3-6AC3-4D5A-AC98-C1CE61ECE35C

Q30439565-1C8C62EC-FA3D-4C2F-A8BB-23A7603E36AF

Q30439565-1C92AFCA-DB46-4FDC-B2F2-9645E2B0BBC5

Q30439565-1CD38B81-001A-4650-8622-A74915C6C80C

Q30439565-1F2A6BE5-CDFC-4F59-8A5C-2F1895A1F51B

Q30439565-2BBEAFC7-6433-45DC-A947-435DB540EB22

Q30439565-315C06D9-6F1E-4BFB-B201-DAF06CEDF49E

Q30439565-31DD63F8-B1A1-46EC-A71A-841A8D08C63B

P304

Q30439565-7354F2D0-2DC8-4D4B-AFEC-581CBB35F744

P31

Q30439565-9A19C8D6-A47F-4FC7-9FAD-F44E15662604

P356

Q30439565-766EE185-0C19-4730-B262-33047499604A

P433

Q30439565-9EB065E1-F4FB-4AC4-B7CE-C99C9E223A0A

P478

Q30439565-58E9B532-758E-42FE-A138-82B90587F209

P50

Q30439565-88CBB761-458E-487C-B8AA-4B8F84327A89

P577

Q30439565-662FC518-160F-4946-BBB6-B9FAC8878B88

P5875

Q30439565-7943E782-402A-4323-A335-91D9831108C8

P698

Q30439565-3AB4A71A-9E03-4467-B9AD-66D0AC9781FE

P921

Q30439565-E105D6C1-D59C-4097-BD89-B37E2517C405

P932

Q30439565-0DD00FA9-1AA1-4CF1-B428-C0B13DD396BA

P356

15228517-2008-005

P1433

P1476

Phase II study of temozolomide ...... agnosed glioblastoma in adults

@en

P2093

Abigail Ciampa

http://www.w3.org/2001/XMLSchema#string

Alona Muzikansky

http://www.w3.org/2001/XMLSchema#string

Andrea Laforme

http://www.w3.org/2001/XMLSchema#string

David Schiff

http://www.w3.org/2001/XMLSchema#string

Debra C Gigas

http://www.w3.org/2001/XMLSchema#string

Jan Drappatz

http://www.w3.org/2001/XMLSchema#string

Janina A Longtine

http://www.w3.org/2001/XMLSchema#string

John W Henson

http://www.w3.org/2001/XMLSchema#string

Judah Folkman

http://www.w3.org/2001/XMLSchema#string

Keith L Ligon

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Celecoxib for the prevention of sporadic colorectal adenomas

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

P304

300-308

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1215/15228517-2008-005

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5450223

http://www.w3.org/2001/XMLSchema#string

P698

18403492

http://www.w3.org/2001/XMLSchema#string

P921

P932

2563052

http://www.w3.org/2001/XMLSchema#string